|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.19 CNY | +0.06% |
|
-2.57% | +13.62% |
| 11:31pm | Yiling Pharmaceutical's Qifang Bitong Tablets Placed in China's Insurance Drug List | MT |
| 11-28 | Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules | MT |
| Capitalization | 30.39B 4.3B 3.7B 3.46B 3.23B 5.96B 387B 6.48B 40.49B 15.63B 183B 16.13B 15.79B 668B | P/E ratio 2025 * |
24.7x | P/E ratio 2026 * | 21.5x |
|---|---|---|---|---|---|
| Enterprise value | 29.97B 4.24B 3.64B 3.41B 3.18B 5.88B 381B 6.39B 39.92B 15.41B 180B 15.91B 15.57B 659B | EV / Sales 2025 * |
3.24x | EV / Sales 2026 * | 2.84x |
| Free-Float |
42.61% | Yield 2025 * |
1.38% | Yield 2026 * | 1.6% |
| 1 day | +0.06% | ||
| 1 week | -2.57% | ||
| Current month | -2.57% | ||
| 1 month | -2.83% | ||
| 3 months | +10.98% | ||
| 6 months | +25.71% | ||
| Current year | +13.62% |
| 1 week | 17.76 |  | 19.1 |
| 1 month | 17.76 | | 21.58 |
| Current year | 12.41 | | 21.58 |
| 1 year | 12.41 | | 21.58 |
| 3 years | 12.41 | | 53.79 |
| 5 years | 12.41 | | 53.96 |
| 10 years | 7.08 | | 53.96 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiang Jun Wu
CEO | Chief Executive Officer | 50 | 2013-03-31 |
Chen Guang Li
DFI | Director of Finance/CFO | 52 | 2018-04-23 |
Qiu Lian Zhang
PRN | Corporate Officer/Principal | 55 | 2020-01-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Yi Ling Wu
CHM | Chairman | 76 | 2012-08-30 |
Xiang Jun Wu
BRD | Director/Board Member | 50 | 2010-08-30 |
Chen Guang Li
BRD | Director/Board Member | 52 | 2018-05-16 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.9% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.06% | -2.57% | +6.87% | -62.97% | 4.3B | |
| +0.51% | -0.09% | -17.70% | -31.11% | 6.48B | |
| +0.26% | +2.22% | +45.15% | +57.01% | 4.39B | |
| +0.80% | +1.65% | -16.45% | +23.33% | 4.37B | |
| -0.26% | +4.07% | -7.48% | -12.54% | 3.56B | |
| +0.20% | +0.13% | +5.50% | +28.99% | 3.24B | |
| +0.30% | -0.06% | -0.82% | -31.47% | 2.53B | |
| -0.40% | +0.16% | +9.85% | +0.24% | 1.99B | |
| -0.09% | +0.96% | -0.90% | +59.67% | 1.76B | |
| +0.12% | -0.23% | +1.07% | +49.87% | 1.67B | |
| Average | +0.15% | -0.74% | +2.51% | +8.10% | 3.43B | |
| Weighted average by Cap. | +0.23% | -0.73% | +1.47% | +1.12% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 9.23B 1.31B 1.12B 1.05B 980M 1.81B 118B 1.97B 12.3B 4.75B 55.52B 4.9B 4.8B 203B | 10.2B 1.44B 1.24B 1.16B 1.08B 2B 130B 2.18B 13.59B 5.25B 61.32B 5.41B 5.3B 224B |
| Net income | 1.23B 174M 149M 140M 131M 241M 15.65B 262M 1.64B 633M 7.39B 653M 639M 27.03B | 1.42B 201M 172M 162M 151M 278M 18.06B 303M 1.89B 730M 8.53B 753M 737M 31.18B |
| Net Debt | -425M -60.12M -51.68M -48.41M -45.12M -83.35M -5.41B -90.66M -566M -219M -2.56B -226M -221M -9.34B | -1.44B -203M -174M -163M -152M -281M -18.27B -306M -1.91B -738M -8.63B -762M -746M -31.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 18.19 ¥ | +0.06% | 21,686,390 |
| 25-12-04 | 18.18 ¥ | -3.35% | 37,287,980 |
| 25-12-03 | 18.81 ¥ | +0.86% | 36,308,180 |
| 25-12-02 | 18.65 ¥ | -1.06% | 20,766,500 |
| 25-12-01 | 18.85 ¥ | +0.96% | 26,090,530 |
End-of-day quote Shenzhen S.E., December 04, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 002603 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition